Loading...
Market
Significant improvement in overall survival rates in final GALAXIES Lung-201 study results by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Final study results published in medical journals or presented at conferences
Story
iTeos and GSK Show Promising Anti-TIGIT Results in Lung Cancer Study at ESMO 2024
Sep 14, 2024, 06:32 AM
iTeos Therapeutics and GSK have announced promising results from their mid-stage GALAXIES Lung-201 study, which investigates the combination of Belrestotug and Dostarlimab in first-line, PD-L1 high non-small cell lung cancer patients. The study, presented at the European Society for Medical Oncology (ESMO) 2024 conference, showed a clinically meaningful objective response rate at every dose level in a follow-up interim analysis. This development has renewed cautious optimism around anti-TIGIT immunotherapy drugs, which have faced setbacks in the past. The positive response rates suggest that TIGIT could be a viable target for lung cancer treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Less than 50 months • 25%
50-60 months • 25%
60-70 months • 25%
More than 70 months • 25%
PFS < 6 months • 25%
PFS 6-8 months • 25%
PFS 8-10 months • 25%
PFS > 10 months • 25%